Black Diamond Therapeutics (BDTX) Net Cash Flow (2019 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Net Cash Flow came in at $9.1 million in Q1 2026, down 85.35% YoY from $62.0 million in Q1 2025, and up 192.01% on a QoQ basis from -$9.9 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Net Cash Flow (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 8 years of Net Cash Flow data on file, last reported at $9.1 million in Q1 2026.
- Quarterly Net Cash Flow fell 85.35% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.3 million (down 193.62% YoY) and the FY2025 annual result came in at -$15.4 million, up 21.99% from the prior year.
- Net Cash Flow improved to $9.1 million in Q1 2026, from -$9.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $62.0 million in Q1 2025 to a low of -$68.4 million in Q2 2025.
- A 5-year average of -$2.1 million and a median of $874000.0 in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow surged 918.0% — and 2025, when it tumbled 1025.7%.
- Tracing BDTX's Net Cash Flow over 5 years: stood at -$19.6 million in 2022, then jumped by 91.08% to -$1.8 million in 2023, then soared by 841.87% to $13.0 million in 2024, then sank by 175.91% to -$9.9 million in 2025, then soared by 192.01% to $9.1 million in 2026.
- The last three Net Cash Flow figures came in at $9.1 million (Q1 2026), -$9.9 million (Q4 2025), and $874000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | -10.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.88 Mn |
| Jun 30, 2026 | -10.88 Mn |
| Mar 31, 2026 | 9.08 Mn |
| Mar 31, 2026 | 9.08 Mn |
| Dec 31, 2025 | -9.87 Mn |
| Dec 31, 2025 | -9.87 Mn |
| Sep 30, 2025 | 874,000.00 |
| Sep 30, 2025 | 874,000.00 |
| Jun 30, 2025 | -68.43 Mn |
| Jun 30, 2025 | -68.43 Mn |
| Mar 31, 2025 | 61.99 Mn |
| Mar 31, 2025 | 61.99 Mn |
| Dec 31, 2024 | 13.01 Mn |
| Dec 31, 2024 | 13.01 Mn |
| Sep 30, 2024 | -9.38 Mn |
| Sep 30, 2024 | -9.38 Mn |
| Jun 30, 2024 | 7.39 Mn |
| Jun 30, 2024 | 7.39 Mn |
| Mar 31, 2024 | -30.80 Mn |
| Mar 31, 2024 | -30.80 Mn |